About: Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.70 (-3.02%)
ANNX NASDAQ Annexon Inc
Annexon Inc share price
Atividade de preço de ANNX
Último preço
$ 3,700
Variação (24h)
-0,12 USD (3,02%)
Volume
977.59K
Volume (média 4 sem.)
-
Abertura
$ 3,78
Variação do dia
$ 3,64 - $ 3,85
Fechamento anterior
$ 3,81
Último negócio
23 Oct, 5:19 pm GMT+0
Atrasado
23 Oct, 5:19 pm GMT+0
ANNX price performance
Atrasado
23 Oct, 5:19 pm GMT+0
quote.marketSignals